Patents Assigned to Incyte Corporation
  • Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III
    Patent number: 10975085
    Abstract: The present invention is related to processes for preparing a composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, and related synthetic intermediate compounds. This compound is useful as an inhibitor of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 13, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jiacheng Zhou, James D. Rodgers, Haisheng Wang
  • Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
    Patent number: 10975088
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: April 13, 2021
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Salts of an LSD1 inhibitor and processes for preparing the same
    Patent number: 10968200
    Abstract: The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
    Patent number: 10968221
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula IIa, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10947230
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: March 16, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yaping Sun, Wenqing Yao, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Fenglei Zhang
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 10947227
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 16, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 10934288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 2, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
    Patent number: 10919901
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: February 16, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 10919912
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: February 16, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Heterocyclic compounds as immunomodulators
    Patent number: 10906920
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: February 2, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Benzothiazole compounds and uses thereof
    Patent number: 10899755
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • Processes and intermediates for making a JAK inhibitor
    Patent number: 10899736
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Dengjin Wang, Pingli Liu, Yongzhong Wu, Jiacheng Zhou
  • Heteroaryl amide compounds as sting activators
    Patent number: 10875872
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: December 29, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 10874616
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 29, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Topical formulation for a JAK inhibitor
    Patent number: 10869870
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: December 22, 2020
    Assignee: Incyte Corporation
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Amorphous solid form of a BET protein inhibitor
    Patent number: 10858372
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: December 8, 2020
    Assignee: Incyte Corporation
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 10851105
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 1, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Liang Lu, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 10844069
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: November 24, 2020
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Pyrimidinones as PI3K inhibitors
    Patent number: 10829502
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: November 10, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
    Patent number: 10828290
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: November 10, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang